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Abstract: Background: We compared the efficiency of two MRI diffusion weighted imaging (DWI)
techniques: DWI with SPIR (DWISPIR) and DWI with STIR (DWISTIR), to estimate their eligibility
for quantitative assessment of Crohn’s disease activity in children and adults. Methods: In inflamed
terminal ileum segments (n = 32 in adults, n = 46 in children), Magnetic Resonance Index of Activity
(MaRIA) was calculated, ADC values of both DWI techniques were measured, and the corresponding
Clermont scores calculated. ADC values of both DWI techniques were compared between both and
within each patient group, assessing their mutual correlation. Correlations between MaRIA and the
corresponding ADC values, and Clermont scores based on both DWI techniques were estimated.
Results: No correlation between ADC of DWISPIR and DWISTIR was observed (rho = 0.27, p = 0.13 in
adults, rho = 0.20, p = 0.17 in children). The correlation between MaRIA and Clermont scores was
strong in both techniques—in SPIR, rho = 0.93; p < 0.0005 in adults, rho = 0.98, p < 0.0005 in children,
and, in STIR, rho = 0.89; p < 0.0005 in adults, rho = 0.95, p < 0.0005 in children. The correlation
between ADC and MaRIA was moderate negative for DWISTIR (rho = 0.93, p < 0.0005 in adults,
rho = 0.95, p < 0.0005 in children), but, in DWISTIR, no correlation between ADC and MaRIA score
was observed in adults (rho = −0.001, p = 0.99), whereas children presented low negative correlation
(rho = −0.374, p = 0.01). Conclusions: DWISTIR is not suitable for quantitative assessment of Crohn’s
disease activity both in children and adult patients.
Keywords: MR enterography; terminal ileitis; diffusion-weighted imaging; DWI; DWIBS; ADC;
MaRIA; Clermont score; DWI fat suppression techniques
1. Introduction
Crohn’s disease (CD) is an idiopathic chronic relapsing inflammatory bowel condition, which
manifests itself in fistulae, abscesses and strictures [1]. The chronic inflammation causes progression of
intestinal complications, requiring surgery in most cases [2,3]. It is known that active therapy including
adjustment of medication reduces the number of complications and the need for surgery [1]. The
goal of treatment for CD is either resolution of abdominal complaints and endoscopically confirmed
remission, or resolution of inflammatory signs in cross-sectional imaging [4]. Since 2019, according to
ECCO-ESGAR Guideline for Diagnostic Assessment in inflammatory bowel diseases, cross-sectional
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imaging modalities are recognised to be an alternative for the evaluation of the disease activity [5].
Magnetic resonance enterography (MRE) is proven to have a great potential for evaluating CD activity,
due to its high soft tissue resolution, non-invasiveness and lack of ionizing radiation, and ability to
obtain findings not only within but also around the bowel wall [6].
To assess CD activity, a number of MRI scoring systems have been developed for standardising
the measured outcomes [6]. Among these indices, Magnetic Resonance Index of Activity (MaRIA) is
the only approved MRE-based score, having the strongest validation data based on a large population
of patients [7]. However, MaRIA score relies on the measurement of enhanced gadolinium contrast
media known to be related to systemic nephrogenic fibrosis [8], as well as accumulation of gadolinium
deposits in the brain [9] and other body tissues, such as skin, liver and bones [10]. As patients
with CD usually require multiple follow-up examinations which expose them to a certain risk of
gadolinium accumulation, solutions allowing replacement of the contrast medium administration are
of importance.
Diffusion-weighted imaging (DWI) has been shown to have potential as a replacement of the
contrast media, by detecting lesions prior their appearance in conventional images [11]. It also
outperforms the T1 post-contrast dynamic series [12–15]. DWI is proven to be useful for the detection
of inflammation in CD [16,17], and, when added to the MRE protocol, it yields increased sensitivity in
diagnostics of CD than conventional MRE alone [18] thus potentially supporting early diagnosis of CD.
DWI also has a very important role in evaluating CD activity, which allows assessment of treatment
efficacy [7].
DWI can be measured quantitatively with apparent diffusion coefficient (ADC). ADC of DWI is
proven to be as useful as the relative contrast enhancement (RCE) used for calculation of MaRIA [19].
A DWI-based MaRIA, or Clermont score, is designed to serve as an alternative to avoid gadolinium
administration [17] and is reported to have excellent correlation compared to MaRIA [20]. This index
still is to be validated by confirmatory studies.
Due to the low sensitivity to motion-induced phase errors and advantages of short imaging
times, DWI normally uses single-shot echo-planar imaging (EPI) acquisition, related to the presence of
susceptibility artefacts at tissue interfaces [21] and chemical shift-induced ghosting artefacts deflecting
the fat signal several pixels away from the water signal. To avoid these artefacts, DWI protocols should
include fat saturation techniques [22,23]. These techniques are simply divided into two categories—fat,
or spectral, selective and non-selective ones.
Among fat selective techniques, chemical shift selective fat suppression (CHESS) is a common
fat saturation technique in which an excitation pulse with a bandwidth selective to the resonance
frequency of fat is applied, followed by a spoiler dephasing gradient [24]. There are also two fat
selective hybrid sequences. In spectral attenuated inversion recovery (SPAIR) the fat signal is inverted
with an adiabatic spectrally selective pulse, and acquisition starts from the moment of inversion time
(TI) that nulls the fat signal. Spectral pre-saturation with inversion recovery (SPIR), in turn, is a hybrid
sequence with a spectrally selective inversion pulse is applied tuned to fat frequency [24]. After the TI,
a conventional 90◦ spin-echo pulse is applied to saturate just the fat signal [25]. All these techniques
use spectrally selective pulses suppressing signal from only fat protons.
Alongside fat selective saturation techniques, the DWI weighted sequence with Short Tau Inversion
Recovery (STIR) fat suppression technique is also used. STIR is an inversion recovery technique based
on the difference in relaxation between water and fat tissues, which have a much shorter T1 relaxation
time compared to other tissue types. An inversion pulse is applied before the excitation pulse; the
spins of all tissues invert and then perform T1 relaxation. By selecting the inversion time (TI) such
as the longitudinal magnetisation of fat at that time is zero, fat spins will not participate to the MR
signal [26]. STIR-based DWI had been developed in 2004 by the research group of Takahara who named
it Diffusion Weighted Imaging with Background Body Signal Suppression (DWIBS). This sequence
allows free breathing, permitting multiple slice excitation and signal averaging over an extended
period to average motion [27]. When compared to the selective fat saturation techniques, while
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chemical fat selective saturation techniques are more influenced by magnetic field inhomogeneities [28]
the use of DWI with non-selective STIR allows robust and more homogenic fat suppression within
large body regions [27,28] including off-center localisations [24], providing a higher contrast-to-noise
ratio (CNR) [23], insensitivity to magnetic field inhomogeneities, and decreased image distortion [29]
making it suitable for scanning large areas [23]. It also suppresses the signals from bowel content [29].
DWIBS was initially developed for the whole-body imaging of oncology patients to detect tumour
relapse and metastases [27], but it is now used in many other applications including detecting
inflammatory lesions, abscesses, intravascular thrombi, and visualisation of the peripheral nerves [23].
DWI with STIR technique is reported to have better image quality and less image artefacts when
compared to conventional, or spectral selective, DWI [30]. Regarding ADC analysis, DWI with STIR is
proven to be superior over conventional DWI, in the assessment of breast lesions [31]. The American
College of Radiologists recommends including DWI with STIR in standard MRE protocols for imaging
of the gastrointestinal tract [32]. Using DWI sequence with STIR in MRE examinations is further
recommended by a number of authors [33,34]. It is also reported to be used in the assessment of CD
activity [35]. The non-selectivity of STIR can be a disadvantage if tissues contain other substances
with short T1 time, such as methaemoglobin, mucoid tissue, proteinaceous material, and melanin [24].
Another disadvantage of STIR-based fat suppression, is decreased SNR by partial loss of proton signal
during the inversion time [29], causing grainy image appearance. Nevertheless, the free breathing
DWIBS as DWI sequence with STIR is one of the most important DWI-related discoveries, allowing
whole body imaging [27], and so improving diagnosis in oncology (tumour staging, detection of
tumour relapse, monitoring response to therapy) [36]. Despite the reduced SNR, DWIBS contributes in
improved detection of subtle lesions due to higher CNR [23]. DWI with STIR is reported to be feasible
for the identification and characterisation of lymph nodes in patients with uterine cervical cancer [37].
ADC calculated from DWISTIR (ADC-DWISTIR) tracking images is reported to be superior over ADC of
DWISPIR (ADC-DWISPIR) in differentiating between malignant and benign breast lesions [31] whilst
also being non-dependent on motions [38], important in bowel imaging. However, there have been no
studies published on comparison between DWI sequences with non-selective STIR and chemical fat
selective DWI techniques for quantitative assessment of CD activity.
The aim of our study was to compare the performance of DWI sequences with fat selective Spectral
Presaturation with Inversion Recovery (SPIR) (DWISPIR) and non-selective STIR, or DWIBS, (DWISTIR),
in quantitative assessment of active CD in the terminal ileum through the following measures:
(1) Measuring ADC values of DWI with SPIR (ADC-DWISPIR) and DWI with STIR (ADC-DWISTIR) in
groups of adult and paediatric patients, comparing each individual patient group and assessing
their mutual correlation,
(2) comparing ADC- DWISPIR and ADC-DWISTIR values between the groups of adults and
pediatric patients,
(3) estimating correlations of ADC-DWISPIR and ADC-DWISTIR values with the corresponding
MaRIA, calculated from the contrast–enhanced sequences within the same bowel segments,
(4) calculating Clermont scores values based on ADC-DWISPIR and ADC-DWISTIR and estimating
their correlation with MaRIA within the same bowel segments.
2. Materials and Methods
2.1. Patient Population
In this prospective observational cross-sectional study, the patients underwent MRE examination
between April 2016 and April 2019. All patients involved in the research had either symptomatic
CD, or underwent MRE examination for monitoring the disease course under treatment. The faecal
calprotectin levels in all study subjects exceeded 1000 µg/g. The inclusion criteria were: proven active
non-stricturing non-penetrating CD in the terminal ileum, presenting with thickened bowel wall
(thickness > 3 mm), presence of mural oedema (hyperintensity of the bowel wall in T2-weighted
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images compared to the psoas muscle) [39], signs of restricted diffusion in both of DWI sequences with
SPIR and STIR presenting with high SI in DWI tracking images of b = 800 s/mm2 along with low signal
intensity (SI) in the ADC map, and early mucosal hyperenhancement in the post-Gd series [40]. The
exclusion criteria were: locations of CD other than the terminal ileum, bowel thickness less than 3 mm,
dynamic blurring in either of the DWI or T1 post-Gd images, inability to locate active bowel wall
inflammation in both DWI sequences, with SPIR and STIR, and post-Gd T1 within one and the same
segments. The study was performed in accordance with the Declaration of Helsinki and approved by
the Ethics committee of Riga Stradin’s University on 10 September 2015, its permission number was
6/10.09.2015.
2.2. MRI Technique
All patients fasted for 6 h prior the MRE examination, being allowed to intake only water. No
bowel cleansing was carried out. The bowel distension was maintained with 1.000–1.500 mL of 2.5%
mannitol solution, consumed slowly before the MRE procedure for 45 min. After that, patients were
asked to lie in the right decubitus position, and they received another 250 mL of 2.5% mannitol solution
to intake slowly for another 20 min. The MRE examinations were performed with a 1.5T scanner
(Ingenia, Philips Medical Systems, Best, The Netherlands) covering the region from the diaphragm to
the pelvis with a 16-element phased array body coil. The patients were scanned in the prone position.
The MRE protocol included:
(1) coronal bTFE (Balanced Turbo Field Echo) cine sequence for real-time assessment of the
bowel peristalsis,
(2) axial DWI sequence with SPIR, using diffusion factors b fixed at 0, 600 and 800 s/mm2, with
corresponding ADC maps,
(3) axial DWIBS sequence (DWI with STIR), using diffusion factors b fixed at 0, 600 and 800 s/mm2,
with corresponding ADC maps,
(4) axial and coronal T2-weighted sequences without fat suppression (T2 TSE),
(5) axial and coronal T2-weighted sequences with fat suppression (T2 SPAIR),
(6) coronal T2 fat suppression magnetic resonance cholangiopancreatography (MRCP) sequence
with radial 3D reconstructions,
(7) coronal T1-weighted dynamic postcontrast images e-THRIVE (T1 high-resolution isotropic
volume excitation), followed by delayed post-contrast axial e-THRIVE images.
The scanning parameters of the DWISPIR and DWISTIR (DWIBS) protocols are given in Table 1. To
reduce bowel peristalsis, hyoscine butylbromide (Buscopan, Sanofi, Athens, Greece) was intravenously
administered, prior to the DWISPIR and DWISTIR sequences and the coronal dynamic contrast sequences.
The dosage was 10 mg in patients under 50 kg and 20 mg in patients 50 kg or above, diluted in 20 mL
of saline solution.
Table 1. Scanning parameters of DWISPIR and DWISTIR techniques included in the MRE protocol.
Scanning Protocol DWISPIR 1 DWISTIR (DWIBS)_ 2
Sequence SE-EPI 3 STIR-EPI 4
Mode Single shot Single shot
Coil SENSE 5 body SENSE body
Slice orientation Axial Axial
FOV 6 RL
7 400 mm, AP 8 350 mm, FH 9
303 mm
RL 400 mm, AP 350 mm, FH
303 mm
ACQ 10 voxel size
RL 3.03 mm × AP 3.57 mm × slice
thickness 6 mm
RL 2.50 mm × AP 2.98 mm × slice
thickness 6 mm
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Table 1. Cont.
Scanning Protocol DWISPIR 1 DWISTIR (DWIBS)_ 2
Reconstruction voxel size RL 1.79 mm × AP 1.79 mm × slicethickness 6 mm
RL 1.39 mm × AP 1.39 mm × slice
thickness 6 mm
Fold-over suppression No No
Reconstruction matrix 224 288
SENSE Yes Yes
P reduction (AP) 2 2.5
Number of stacks 1 1
Type Parallel Parallel
Slices 46 46
Slice gap (mm) 0.6 0.6
Slice orientation Transverse Transverse
Fold-over direction AP AP
Fat shift direction A P
TE 11 66 ms 78 ms
TR 12 1426 ms 7055 ms
TI 13 - 180 ms
Fast imaging mode EPI 14 EPI
Flip angle 90◦
Fat suppression SPIR STIR
b factors 0, 600, 800 s/mm2 0, 600, 800 s/mm2
Respiratory compensation Trigger No
Number of signal averages 3 5
Total scan time 4 min. 12 s 5 min. 56 s
1 DWISPIR—Diffusion-Weighted imaging with Spectral Presaturation with Inversion Recovery technique.
2 DWISTIR—Diffusion-Weighted Imaging with Short-Tau Inversion Recovery. 3 SE-EPI—Spin Echo—Echo
Planar Imaging. 4 STIR-EPI—Short T1 Inversion Recovery—Echo Planar Imaging. 5 SENSE—SENSitivity
Encoding. 6 FOV—Field of View. 7 RL—Right-Left direction. 8 AP—Anterior-Posterior direction.9 FH—Foot–Head
direction.10 ACQ—Acquisition. 11 TE—Echo Time. 12 TR—Repetition Time. 13 TI—Inversion Time. 14 EPI—Echo
Planar Imaging.
2.3. MR Image Analysis
The altered locations of the terminal ileum were identified and divided into approximately 3 cm
long segments. The total number of segments was 78, 32 in adults and 46 in paediatric patients. In each
segment, wall thickness was measured in mm, presence of ulcers (present or absent) was estimated,
and six measurements of ADC-DWISPIR and ADC-DWISTIR in the corresponding DWISPIR and DWISTIR
tracking images of b = 800 s/mm2 were performed in each segment, in the zone of the highest signal
intensity within the bowel wall. Six measurements of the wall signal intensity were taken in the
same location both before (WSI-preGd) and after (WSI-postGd) administration of gadolinium contrast
medium, in the site with the highest SI in the postcontrast images. Six measurements of standard
deviation (SD) representing the image noise were performed outside the body before (SD-preGd)
and after (SD-postGd) administration of gadolinium contrast medium [39]. The mean value of all
measurements was used for calculations. In each altered bowel segment, MaRIA was calculated using
the following formula:
MaRIA = 1.5 ×wall thickness (mm) + 0.02 × RCE + 5 × oedema + 10 × ulcers,
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where the presence or absence of ulcers and oedema was rated as 1 or 0, accordingly. RCE was
calculated as follows:
RCE = (WSI-postGd −WSI-preGd)/(WSI-preGd)) × 100 × (SD-preGd/SD-postGd),
where the SD-preGd and SD-postGd corresponded to the mean of the six SD values of SI, measured
outside of the body before and after gadolinium administration, accordingly [39]. Since oedema was
one of the inclusion criteria representing inflammation, it was always present, and its rating was
always equal to 1. The Clermont score, or DWI-MaRIA, for both DWISPIR and DWISTIR sequences, was
calculated per formula [20]:
DWI-MaRIA = 1.646 × bowel thickness − 1.321 × ADC + 5.613 × oedema + 8.306 × ulceration + 5.039
The i/v gadolinium contrast agent used before October 2018 for all adult patients and all but two
children was gadodiamide (Omniscan 0.05 mmol/mL, GE Healthcare, Cork, Ireland, dosage 0.2 mL/kg,
or 0.1 mmol/kg). Gadobutrol (Gadovist 1 mmol/mL, Bayer, Berlin, Germany, dosage 0.1 mL/kg, or
0.1 mmol/kg) was used for the two paediatric patients examined after October 2018.
The ADC, WSI and SD measurements were performed using 4–9 mm2 oval region of interest
(ROI). The image analysis and the measurements were performed by one radiologist with 19 years’
experience in abdominal MRI imaging. The review of images and ADC measurements were performed
using a dedicated Philips Intellispace Portal postprocessing server, v. 5.0 (Philips Medical Systems,
Best, The Netherlands, 2014). The WSI and image noise measurements were performed using Clear
Canvas DICOM Viewer, v. 13.2 (Synaptive Medical, Toronto, ON, Canada, 2019).
2.4. Statistical Analysis
The statistical analysis was performed using software SPSS 20.0 (IBM Corporation, Armonk,
NY, USA, 2011). The median values with standard deviations for ADC-DWISPIR and ADC-DWISTIR,
MaRIA, DWISPIR-Clermont, and DWISTIR-Clermont scores were calculated. 95% CI was calculated
for median differences. The statistical significance of differences between the groups was determined
using Wilcoxon signed rank test. Spearman’s correlation coefficient was used to assess the correlations
between quantitative parameters. p values of <0.05 (two-tailed) were chosen as a level of statistical
significance. The Bonferroni correction was used to control Type 1 error in multiple comparisons.
3. Results
Seventeen patients: five adults (23, 25, 36, 40 and 57 years old) and 12 children (11 years old;
n = 2, 12 years old; n = 3, 13 years old; n = 1, 14 years old; n = 4, 17 years old; n = 2) were enrolled in
the study. In one adult patient, the duration of medical history prior to the MRE examination was
more than two years in three adult patients—from 6 till 12 months, but in one adult patient, CD was
asymptomatic, of unknown length, and it was detected upon performing a set of infertility tests. In
one paediatric patient, the duration of CD was slightly less than two years, but in the remaining 11
patients the duration of medical history was less than 6 months.
The overview of measured ADC-DWISPIR and ADC-DWISTIR values, as well as calculated values
of MaRIA, DWISPIR-based Clermont score and DWISTIR-based Clermont score, is presented in Table 2.
There was a statistically significant difference of 10.32% (p = 0.02) between the median values
of ADC-DWISPIR in adults and children, appearing lower in children than in adults; no statistically
significant difference (p = 0.38) between ADC-DWISTIR in adults and children was detected. There was
statistically significant difference of 8% (p = 0.03) between ADC-DWISPIR and ADC-DWISTIR values
in adults, appearing lower in DWISTIR, but no statistically significant difference (p = 0.97) between
ADC-DWISPIR and ADC-DWISTIR values in children. The graphical comparative distribution of the
ADC-DWISPIR and ADC-DWISTIR values between both patient groups is shown in Figure 1a,b. The
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graphical comparative distribution of the ADC-DWISPIR and ADC-DWISTIR values within each of the
patient groups is shown in Figure 2a,b.
Table 2. Values of ADC-DWISPIR, ADC-DWISTIR, MaRIA as well as ADC-DWISPIR and ADC-DWISTIR
-based Clermont scores in the groups of adult and paediatric patients.
Measurement N MinimumValue
Maximum
Value Median Value SD
ADC-DWISPIR (mm2/s), adults 32 0.66 × 10−3 2.16 × 10−3 1.26 × 10−3 0.29
ADC-DWISPIR (mm2/s),
children
46 0.18 × 10−3 2.23 × 10−3 1.13 × 10−3 0.31
ADC-DWISTIR (mm2/s), adults 32 0.01 × 10−3 2.37 × 10−3 1.15 × 10−3 0.49
ADC-DWISTIR (mm2/s),
children
46 0.20 × 10−3 2.74 × 10−3 1.16 × 10−3 0.44
MaRIA, adults 32 10.65 36.65 24.43 5.31
MaRIA, children 46 9.96 37.67 22.08 6.67
DWISPIR-based Clermont
score, adults 32 12.85 39.23 26.23 4.76
DWISPIR-based Clermont
score, children 46 13.59 40.74 23.53 5.42
DWISTIR-based Clermont
score, adults 32 5.92 38.78 24.28 4.65
DWISTIR-based Clermont
score, children 46 8.25 39.52 24.39 5.77
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(b) in children.
In all patients of both groups, the MaRIA value corresponded to active disease (i.e., ≥7) [6].
Excluding one patient with the score value of 10.65, MaRIA score values in all adult patients also
corresponded to severe disease (i.e., ≥11). In the paediatric group, in all but three patients, with the
values of 9.95, 10.25 and 10.66, MaRIA values exceeded 11 thus corresponding to severe disease [6].
In all patients of both groups, the DWISPIR-based Clermont score value corresponded not only
to active disease (i.e., >8.4) but severe disease (i.e., ≥12.5). In two adult patients, the DWISTIR-based
Clermont score values (i.e., 5.92 and 8.20) were below the threshold of 8.4 for active disease, however
the values of all other patients corresponded both to active and to severe disease. In one paediatric
patient, the DWISTIR-based Clermont score value (i.e., 8.24) was slightly below the threshold of 8.4 for
active disease; two patients with values of 11.26 and 12.38 corresponded to active disease, and all other
patients corresponded to severe disease [6].
The correlation between ADC-DWISPIR and ADC-DWISTIR was weak and statistically unreliable
in both adults (rho = 0.27; p = 0.13) (Figure 3a) and children (rho = 0.22; p = 0.15) (Figure 3b).
There was a strong and statistically significant correlation between MaRIA and ADC-DWISPIR-based
Clermont score in both adults (rho = 0.93; p < 0.0001) (Figure 4a) and in children (rho = 0.98; p < 0.0001)
(Figure 4b). There was also a strong and statistically significant correlation between MaRIA and
ADC-DWISTIR-based Clermont score in adults (r = 0.89; p < 0.0001) (Figure 5a) and in children (rho = 0.95;
p < 0.0001) (Figure 5b). The correlation between ADC-DWISPIR and MaRIA was moderate negative and
statistically reliable in both adults (r = −0.50, p = 0.004) (Figure 6a) and children (r = −0.54, p < 0.0001)
(Figure 6b). There was no correlation between ADC-DWISTIR and MaRIA (rho = −0.001, p = 0.99) in
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adults (Figure 7a), and low negative statistically reliable correlation (rho = −0.374, p = 0.01) in children
(Figure 7b).
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4. Discussion
The primary goal of treatment for CD is to achieve remission. Although the primary endpoint
of treatment has long been endoscopic remission i.e., mucosal healing [5,39,40], CD is a transmural
inflam ation. Even in patients with sustained mucosal healing, transmural inflammation may
persist [41–43]. It is proven that compared to mucosal healing, transmural healing is related to
improved long-term outcomes, including sustained long-term steroid-free clinical remission, less need
for rescue therapy, less CD-related hospitalisations and CD-related surgery [44]. Therefore, transmural
healing has recently been proposed as a new target for CD treatment [45]. To assess transmural changes,
imaging techniques are required allowing evaluation of the altered intestinal wall along its entire
length and thickness. MRE, being an informative non-invasive radiation-free cross-sectional imaging
modality providing high soft tissue resolution, is proven to have a potential to replace endoscopy in
assessment of inflammatory activity [39].
MaRIA score, developed by the Rimola research team [39], is the only validated index for
measuring inflammatory activity in the ileum distal loop, tested in large patient populations [7] and
ulticenter research [46]. However, multiple gadolinium contrast injections should be avoided, due to
related adverse effects [9–11]. In 2019, this same research group also published a report on the simplified
MaRIA (sMaRIA), based on data from 98 patients, accounting fat stranding, instead of RCE [46].
However, this novelty approach requires larger validation studies. The London index measures the
wall thickness and presence of edema [47], providing an accurate assessment of inflammatory activity,
however cannot be used in estimating disease severity, and thus is not applicable in the evaluation of
therapeutic response upon follow-up examinations [46]. The Clermont score is based on DWI (therefore
called DWI-MaRIA), and it was derived by the research group of Clermont-Ferrand university as an
alternative for MaRIA, replacing RCE with ADC, thus avoiding administration of gadolinium contrast
media. The authors of the Clermont score state it is not only useful in estimation of ileal CD activity,
with excellent correlation with RCE-based MaRIA [20], but also in the detection of ulcers [48] and
prediction of remission after biological therapy [49]. However, the performance of the Clermont score
still should be validated.
In DWI, which the Clermont score is based on, tissue contrast relies on differences of motions
of water molecules among various tissues [50]. In each MRI system, there are several choices of fat
saturation techniques for use with DWI. At our institution, the MR protocol repository for abdominal
imaging contains two types of DWI sequences—DWI with SPIR fat suppression technique and DWIBS
sequence using STIR; their scanning parameters are given in Table 1. When compared to the DWI with
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SPIR, bowel walls in DWIBS visually look sharper and contours of structures are better delineated
(Figure 8). Precise delineation of inflammatory lesions could be very important in diagnosis of CD,
which can be subject to delay for up to several years [51], especially in locations not assessible by
endoscope, where cross-sectional imaging could be the only solution to reveal inflammation. Therefore,
due to better delineation of bowel walls in DWI with STIR, our goal was to assess the reliability of
ADC-DWISTIR measurements to be used in calculating the Clermont score, when compared to the
ADC-DWISPIR values.
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Figure 8. DWISPIR (a) and DWISTIR (b) tracking images of b = 800 s/mm2 images of 40 years old male
patient with active CD. Inflamed bowel walls present high signal intensity. Despite decreased SNR
causing graininess in the images, the resolution of inflamed bowel and delineation of contours is better
in DWISTIR image (black arrow) as compared to the DWISPIR image (white arrow).
In the current literature, there are no strictly defined recommendations regarding the best fat
suppression techniques to be used in DWI for evaluation of CD activity. Sin ha et al. and Park
recommend using DWI sequ nce with STIR within protocols for assessment of gastrointesti al tract
mentioni g the role of ADC measurement [33,34]. The American Coll ge of Radiologists r commends
that DWI sequence with STIR should be included within the MRE protocol [32]. The free-breathing
t hnique affords multiple averages, thus leading to better SNR, so probably having advantages in
p rforming measurements of ADC [29]. To our knowledge of using ADC in the assessment of bowel
inflammation, Kiryu et al. and Caruso et al. are the only research teams reporting DWI with STIR used
in ADC measurem nts for qu ntitative ass ssme t of bowel information [35,52]. The Caruso t am also
used this ADC exactly to calcul te the Clermont score. However, s veral th r authors emphasise
using free breathing techniques [13,14,18–20,53–55], without specifying the fat saturation method us d
wit DWI. T erefore, there is a ch nce that researchers consider navigator triggered DWI sequences
with SPIR, SPAIR, and CHESS requiring l ss signal averaging than free br thing tech iques, however,
in some of these studies, the related fat saturation technique could theoretically be STIR. Consequently,
if the article does not explicitly state the technique of fat saturation, it is impossible to judge exactly
which one is used.
Initially, we calculated the correlation between ADC-DWISPIR and ADC-DWISTIR with the
expectation of a good correlation. To our surprise, although ADC-DWISPIR and ADC-DWISTIR visually
seemed to be comparable, we observed almost no correlation between ADC-DWISPIR and ADC-DWISTIR
measured in one and the same bowel segments in both adults (rho = 0.27; p = 0.13) and children
(rho = 0.22; p = 0.15). Although DWISTIR is performed under free breathing, and availability of both
repeated stimulations and acquisitions contributes to improved SNR and both spatial and temporal
resolution [30] the allowance of respiratory motion in DWISTIR, means that slice levels of images
obtained with different b-values may not be identical. Since DWIBS employs multiple slice excitations,
slice levels of images obtained with the same b-value may be different [29]. The weak correlation
between ADC-DWISPIR and ADC-DWISTIR values may also be impacted by the conceptually different
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fat suppression mechanisms of SPIR and STIR, on ADC values of the intestinal wall in relation to
histopathological characteristics of bowel inflammation, due to differences in gut wall histopathology
in adults and children. This issue will be discussed further in the article.
Within the study, the ADC-DWISPIR and ADC-DWISTIR values were analysed in two dimensions:
(1) ADC values of both adults and children were compared within a single fat suppression technique,
and we observed statistically significant ADC-DWISPIR difference between adults and children
(1.31 × 10−3 mm2/s, SD 0.29, vs. 1.16 × 10−3 mm2/s, SD 0.31; p = 0.02), with 12.12% lower ADC
values in children compared to adults, but no statistically significant difference between the
ADC-DWISTIR values in adults and children (1.09 × 10−3 mm2/s, SD 0.49, vs. 1.20 mm2/s × 10−3,
SD 0.44; p = 0.38);
(2) both DWISPIR and DWISTIR techniques were compared within one patient group, both in adults
and children. In this case, the analysis showed difference of 16.73% between ADC-DWISPIR
and ADC-DWISTIR values in adults, being lower in DWISTIR (1.31 × 10−3 mm2/s, SD 0.29, vs.
1.09 × 10−3 mm2/s, SD 0.49; p = 0.03), but did not show difference between ADC-DWISPIR and
ADC-DWISTIR values in the children’s group (1.16 mm2/s × 10−3, SD 0.31, vs. 1.20 × 10−3 mm2/s,
SD 0.44, p = 0.97).
These observations raise questions about why ADC-DWISPIR values are lower in paediatric
patients than in adults whilst no difference in ADC-DWISTIR between adult and paediatric patients is
observed, and why the ADC-DWISTIR values are lower than ADC-DWISPIR in adults, whilst there is
no difference between ADC-DWISPIR and ADC-DWISTIR values in pediatric patients. In answering
these questions, either a differing histopathological pattern in adult and paediatric CD, or differences
between the fat suppression mechanism of DWISPIR and DWISTIR techniques influences ADC values,
or combination of both factors must be taken into account.
To interpret our results, it is necessary to consider the pathophysiological characteristics of the
tissue, the physical basis of both DWI sequences and the duration of CD history. Although the exact
cause of the restricted diffusion in CD still remains unknown, the three ruling theories considered are as
follows: (1) narrowing of extracellular space in active CD (caused by presence of oedema and increased
cell density due to migration of inflammatory cells, mostly lymphocytes), formation of lymphoid
aggregates into the lamina propria and submucosa of the inflamed wall segments (Figure 9a), presence
of dilated lymphatic vessels and epithelioid granulomas, and formation of micro-abscesses) [56–59],
(2) increased perfusion, and (3) mural fibrosis [56,57]. Although the morphological pattern of CD is
generally similar in adult and pediatric patients [59], the main difference between the histopathology
of pediatric and adult CD, is the more frequent appearance of epithelioid granulomas in the inflamed
bowel wall of children [58,60,61] (Figure 9b).
Whenever analysing the performance of ADC-DWISTIR, the non-selectivity of STIR fat suppression
must be considered. Unlike the SPIR technique which uses spectral selective radiofrequency pulse
suppressing solely the fat signal, STIR technique uses an inversion recovery technique based on the
T1 relaxation time of the tissues examined. Apart from fat having a short T1 time, STIR technique
suppresses other substances of short T1 time, thus adding to decrease of ADC value by suppression of
signal from methaemoglobin, melanin, mucoid tissue, and proteinaceous fluid [24]. When considering
the presence of methaemoglobin, although early mucosal lesions in CD can be associated with the
damage of small capillaries [58], no data on haemorrhagic changes in the blood vessels has been found
in literature. An exception to this is angiitis in the outer part of the bowel wall, which manifests
through the infiltration of inflammatory cells into vascular adventitia, or formation of granulomas
alongside blood vessels. There is no evidence of haemorrhagic lesions [62] containing the products
of methaemoglobin. The deposition of melanin (along with lipofuscin) in the intestinal wall is
characteristic of colonic melanosis, related with the chronic use of laxatives [63], and there is limited
data on its association with CD [64,65]. Given its extremely rare occurrence, the chance of intestinal
melanosis occurring in the patients included in the study is unlikely. The inflammatory bowel wall
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tends to contain crypt abscesses, the contents of which could be considered as both mucoid and
protein-rich tissues. However they are occasional, and are only observed in 19% of patients [62].
However, an additional very important consideration influencing the signal intensity of fine and thin
structures, such as the bowel wall, is the partial volume effect [66], where the voxel is influenced not
only by the properties of the same structure but also by the nature of the adjacent tissues. Typically,
achievable DWI resolution is in the order of 2 mm × 2 mm × 2 mm [67]. In our DWIBS protocol,
the acquisition voxel size is 2.50 mm (RL) × 2.98 AP (AP) × 6 mm (slice thickness) therefore, within
the single voxel, there will be signal contamination from the adjacent media. Since the bowel lumen
contains the viscous and proteinaceous chyme, and occasionally fecal admixture, the ADC-DWISTIR
values will be influenced not only by suppression of the mesenterial fat tissue, but also by saturation
of signal from the bowel content with short T1 relaxation time. Therefore, when measured at a short
distance from the intestinal lumen as carried out in the group of adults, ADC-DWISTIR values are




Figure 9. Inflammation of the ileal wall in active chronic CD in 14 y.o. boy, hematoxylin-eosin staining 
(courtesy of Dr. Ivars Melderis), (a) at magnification × 40, (b) at magnification × 100. Infiltration by 
plasma cells, neutrophils and abundant number of lymphocytes is present in the mucosal part of the 
bowel (star), along with epithelioid granuloma (arrow) in the lamina muscularis mucosae providing 
additional contribution for restricted diffusion signal in DWI images in children CD. Due to 
granulation process, there are unaltered red blood cells (arrowheads) in the capillaries of intestinal 
mucosa. The presence of blood degradation products is not detectable in any of the intestinal wall 
layers. 
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Figure 9. Inflammation of the ileal wall in active chronic CD in 14 y.o. boy, hematoxylin-eosin staining
(courtesy of Dr. Ivars Melderis), (a) at magnification× 40, (b) at magnification× 100. Infiltration by
plasma cells, neutrophils and abundant number of lymphocytes is present in the mucosal part of the
bowel (star), along with epithelioid granulo a (arrow) in the lamina muscularis mucosae providing
additional contribution for restricted diffusion signal in DWI images in children CD. Due to granulation
process, there are unaltered red blood cells (arrowheads) in the capillaries of intestinal mucosa. The
presence of blood degradation products is not detectable in any of the intestinal wall layers.
ADC-DWISPIR values are lower in paediatric patients than in adults. This is explained by
differences in medical history. Although all adult patients had active CD, their medical history prior to
the MRE examination was at least six m nths long (except for one patient whose duration of illness was
unknown), whereas all children (except one wit an almost 2-year history of CD) were ex mined no
longer than six months after the o set f s mptoms. Therefore, th edema compo ent in the pediatric
bowel wall was m re pronounced, resulting in a greater diffusion restriction when compared to the
adult patients. The pr sence of epithelioid granulomas may further limit diffusio in the infl med wall.
The explanation of non-difference between ADC-DWISTIR values in a ult and children is more
complex. In children, there is expressiv o dema. Th ROI was positioned at the site with the highest
signal intensity (within the sub ucosal layer of the bowel wall), therefore the distance to t e intestinal
lumen was ufficient to preve t the sign l contamination caused by the partial volume effect. Since the
history of the disease is longer in the group of adult patients, apart from oedema, fibrosis is lso pr sent.
In these locations, the bowel w ll is thinner, and ADC-DWI STIR values are influenced by the partial
volume effect from the bowel c ntent with short T1 time, which artificially lowers the ADC values.
The absence of difference between ADC-DWISPIR and ADC-DWISTIR valu s in the children’s group
could lso be explained with the predominance of the edematous component, which, by increasing the
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thickness of the intestinal wall, does not allow the partial volume effect to affect the ADC-DWISTIR
values measured in the middle of the submucosal layer of the intestinal wall.
The correlation between ADC-DWISPIR and MaRIA was moderately negative in both adults
(r = −0.50, p = 0.004) and children (r = −0.54, p < 0.0005) being worse than reported by the study group
of the Clermont-Ferrand university showing excellent correlation [19,20]. However, in the systematic
review and meta-analysis on using diffusion-weighted MRE for evaluating bowel inflammation in
CD, Choi et al. states that ADC demonstrates a moderate strength of correlation at best and Clermont
score performs better [68]. This is also consistent with our results, since like the studies by the research
group from Clermont-Ferrand university, we also observed excellent correlation between DWI-based
Clermont score and MaRIA in both adults (rho = 0.93; p < 0.0005) and children (rho = 0.98; p < 0.0005).
However, there might a methodological error in using correlation between MaRIA and Clermont score,
as the data to be correlated should be mutually independent, and should not be used if they include
more than one observation in any individual [69]. Apart from RCE used in MaRIA and ADC used
in the Clermont score, all other three variables (wall thickness, presence of edema and presence of
ulcerations), are used in both equations. The use of correlation analysis opposes the conditions in which
correlation can be applied, and in the instances of highest probability, could lead to an overestimation
of the similarity between MaRIA and Clermont score. The correctness of this statement is supported
by the contradiction between correlation of ADC-DWISTIR and the ADC-DWISTIR-based Clermont
Index with MaRIA, as despite no apparent correlation between ADC-DWISTIR and MaRIA (r = −0.001,
p = 0.99) in the adult group, and low negative correlation between ADC-DWISTIR and MaRIA in the
paediatric group (r = −0.37, p = 0.01), the correlation between DWISTIR-based Clermont score and
MaRIA remained strong in both adults (r = 0.89; p < 0.0005) and in children (rho = 0.95; p < 0.0005).
For scanning of the study patients, we used DWISTIR and DWISPIR (DWIBS) sequences included
in the MRE protocol, obtained from the repository provided by the manufacturer. DWISTIR sequence
differs from DWISPIR with the inversion recovery pulse applied. The sharpness of contours in DWISTIR
images always outperforms the DWISPIR series, due to better suppression of background signal and
less T2 “shine through” effect, provided that all scanning parameters (number of signal averages, voxel
size, slice thickness, FOV and DWI directions parameters) are the same. As the voxel size and number
of signal averages does not influence the DWI outcome including the ADC value and these sequences
are designed to provide the best possible performance, we did not modify or harmonise the scanning
parameters used in the protocol.
In our study, we did not use endoscopy as the reference standard but selected the study groups
exclusively by visual MRE findings of CD, i.e., thickened, oedematous bowel wall and markedly
increased SI in the DWI tracking images of b = 800 s/mm2 along with the low SI in the ADC map.
Of course, the lack of correlation with the endoscopic picture could be considered to be a limitation
of the study. However, the literature provides a broad picture of the correlation not only between
MRE and endoscopic findings, but also between MRE and surgery specimens of resected intestinal
segments with certain defined criteria, along with the conclusion that MRI is an informative and
sufficiently accurate method to assess altered bowel wall. Based on these observations, for several
years now, when referring patients for MRE examinations, clinicians do not duplicate their results
with the invasive endoscopy that is also cumbersome for patients. Consequently, in 2019, for the
first time, the ECCO-ESGAR guidelines came up with a revolutionary statement that radiological
cross-sectional imaging methods (and, therefore, MR) can be used as an alternative to endoscopy to
assess CD activity [5]. Therefore, although CD had been endoscopically confirmed in all patients
included in our study, the results of the MRE examination were not duplicated by the endoscopic
and histopathological findings in any cases. It would have been useful to correlate the MR finding
with the histopathological picture of the surgical resection specimens. However, surgical resection
with subsequent histopathological analysis of the specimen, which would provide the most complete
picture of intestinal wall changes, was performed in only one pediatric patient.
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In another related research project, our study team assessed the intra-observer agreement of
measurements of ADC-DWISPIR values, ADC-DWISTIR values, and other components of MaRIA and
Clermont scores—bowel thickness, presence of ulcers and RCE composed from WSE-preGd and
WSI-postGd. The data was recently published. According to our results, there was a systematic
difference in the assessment of ulcers, however, no difference was observed between the measurements
of the bowel wall thickness, ADC values of DWI with SPIR, ADC values of DWI with STIR as well as
measurements performed for assessment of WSI-preGd and WSI post-Gd [70].
In our opinion, the strengths of our research were as follows: (1) the prospective study design,
(2) accurate location-by-location comparison in one and the same bowel segment, (3) explicit ROI size
not being defined in the previous studies on MaRIA and Clermont score, except for when conducted by
the Caruso’s team using the ROI size between 12 and 20 mm2. However, our study also faced several
limitations: (1) the relatively low number of participants in the study groups, (2) the study population
could be subject to selection bias, as both adult and paediatric study groups were not homogenous
regarding the duration of the disease. Paediatric patients included in our study had a relatively shorter
history than the adult patients; (3) in both post-Gd and DWI images, the ROIs were placed on the
site of the maximum SI. After administration of gadolinium contrast media, in some cases the most
intense contrast enhancement was predominantly observed in ileal mucosa, however in other cases
the enhancement was evenly distributed throughout the intestinal wall. In contrast, in both types of
DWI techniques, bowel wall layers were indistinguishable as the diffusion restriction throughout the
intestinal walls was equally intense, which could result in differences of positioning ROI between the
T1 post-contrast and DWI sequences; (4) the MaRIA studies are based on a comparison of the visual
image with the CDEIS—CD endoscopic activity index in adult patients. Unlike adults, estimation of
inflammatory activity in children does not rely on endoscopy findings due to its invasiveness, but
rather on the Pediatric Crohn’s Disease Activity Index (PCDAI), which correlates poorly with the
MaRIA index (r = 0.42, p = 0.016) [6]. Its correlation with Clermont score has not yet been estimated,
so, in children, the utility of Clermont score is still unclear.
5. Conclusions
In Crohn’s disease, DWI MRI sequence with STIR, when compared to DWI MRI sequence with
SPIR, is less reliable and is not suitable for quantitative bowel inflammatory activity assessment to
be used in Clermont score, in both adult and paediatric patients. DWI MRI sequence with STIR is
advisable to provide qualitative visual identification of bowel inflammation foci in adults as well as
paediatric patients.
Author Contributions: Conceptualization, methodology, investigation and writing—original data preparation,
I.A.; investigation, data curation R.P.; resources, writing—review and editing I.F., writing—review and editing, J.P.
and G.K.; supervision, G.K. All authors have read and agreed to the published version of the manuscript.
Funding: This research received no external funding.
Acknowledgments: The authors gratefully acknowledge the generosity of Taro Takahara for his advices regarding
this study, Irena Rogovska for support in processing of statistical data and Rihards Rumnieks for help with
processing of images.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Dulai, P.S.; Singh, S.; Cesarini, M.; Bouguen, G.; Nelson, S.A.; Peyrin-Biroulet, L.; Feagan, B.G.; Ordas, I.;
Sandborn, W.J.; Santillan, C.; et al. Cochrane Database of Systematic Reviews MRI scoring indices for
evaluation of disease activity and severity in Crohn ’ s disease (Methodology Protocol). Cochrane Database
Syst. Rev. 2015, 4, 1–8.
2. Cosnes, J.; Gowerrousseau, C.; Seksik, P.; Cortot, A. Epidemiology and natural history of inflammatory
bowel diseases. Gastroenterology 2011, 140, 1785–1794. [CrossRef]
Diagnostics 2020, 10, 347 18 of 21
3. Sakuraba, H.; Ishiguro, Y.; Hasui, K.; Hiraga, H.; Fukuda, S.; Shibutani, K.; Takai, Y. Prediction of maintained
mucosal healing in patients with Crohn’s disease under treatment with infliximab using diffusion-weighted
magnetic resonance imaging. Digestion 2014, 89, 49–54. [CrossRef] [PubMed]
4. Peyrin-Biroulet, L.; Sandborn, W.; Sands, B.E.; Reinisch, W.; Bemelman, W.; Bryant, R.V.; D’Haens, G.;
Dotan, I.; Dubinsky, M.; Feagan, B.; et al. Selecting Therapeutic Targets in Inflammatory Bowel Disease
(STRIDE): Determining Therapeutic Goals for Treat-to-Target. Am. J. Gastroenterol. 2015, 110, 1324–1338.
[CrossRef] [PubMed]
5. Maaser, C.; Sturm, A.; Vavricka, S.R.; Kucharzik, T.; Fiorino, G.; Annese, V.; Calabrese, E.; Baumgart, D.C.;
Bettenworth, D.; Borralho Nunes, P.; et al. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1:
Initial diagnosis, monitoring of known IBD, detection of complications. J. Crohn’s Colitis 2019, 13, 144K–164K.
[CrossRef] [PubMed]
6. Rozendorn, N.; Amitai, M.M.; Eliakim, R.A.; Kopylov, U.; Klang, E. A review of magnetic resonance
enterography-based indices for quantification of Crohn’s disease inflammation. Therap. Adv. Gastroenterol.
2018, 11, 1756284818765956. [CrossRef] [PubMed]
7. Dohan, A.; Taylor, S.; Hoeffel, C.; Barret, M.; Allez, M.; Dautry, R.; Zappa, M.; Savoye-Collet, C.; Dray, X.;
Boudiaf, M.; et al. Diffusion-Weighted MRI in Crohn’s Disease: Current Status and Recommendations. J.
Magn. Reson. Imaging 2016, 44, 1381–1396. [CrossRef] [PubMed]
8. Perez-Rodriguez, J.; Lai, S.; Ehst, B.D.; Fine, D.M.; Bluemke, D.A. Nephrogenic Systemic Fibrosis: Incidence,
Associations, and Effect of Risk Factor Assessment—Report of 33 Cases. Radiology 2009, 250, 371–377.
[CrossRef]
9. Gulani, V.; Calamante, F.; Shellock, F.G.; Kanal, E.; Reeder, S.B. Gadolinium deposition in the brain: Summary
of evidence and recommendations. Lancet Neurol. 2017, 16, 564–570. [CrossRef]
10. Quattrocchi, C.C.; van der Molen, A.J. Gadolinium Retention in the Body and Brain: Is It Time for an
International Joint Research Effort? Radiology 2017, 282, 12–16. [CrossRef]
11. Baliyan, V.; Das, C.J.; Sharma, R.; Gupta, A.K. Diffusion weighted imaging: Technique and applications.
World J. Radiol. 2016, 8, 785–798. [CrossRef] [PubMed]
12. Oto, A.; Kayhan, A.; Williams, J.T.B.; Fan, X.; Yun, L.; Arkani, S.; Rubin, D.T. Active Crohn’s disease in the
small bowel: Evaluation by diffusion weighted imaging and quantitative dynamic contrast enhanced MR
imaging. J. Magn. Reson. Imaging 2011, 33, 615–624. [CrossRef] [PubMed]
13. Sirin, S.; Kathemann, S.; Schweiger, B.; Hahnemann, M.L.; Forsting, M.; Lauenstein, T.C.; Kinner, S.
Magnetic resonance colonography including diffusion-weighted imaging in children and adolescents with
inflammatory bowel disease: Do we really need intravenous contrast? Investig. Radiol. 2015, 50, 32–39.
[CrossRef] [PubMed]
14. Dubron, C.; Avni, F.; Boutry, N.; Turck, D.; Duhamel, A.; Amzallag-Bellenger, E. Prospective evaluation
of free-breathing diffusion weighted imaging for the detection of inflammatory bowel disease with MR
enterography in childhood population. Br. J. Radiol. 2016, 89, 2–10. [CrossRef] [PubMed]
15. Neubauer, H.; Pabst, T.; Dick, A.; MacHann, W.; Evangelista, L.; Wirth, C.; Köstler, H.; Hahn, D.; Beer, M.
Small-bowel MRI in children and young adults with Crohn disease: Retrospective head-to-head comparison
of contrast-enhanced and diffusion-weighted MRI. Pediatr. Radiol. 2013, 43, 103–114. [CrossRef]
16. Oto, A.; Zhu, F.; Kulkarni, K.; Karczmar, G.S.; Turner, J.R.; Rubin, D. Evaluation of diffusion-weighted MR
imaging for detection of bowel inflammation in patients with Crohn’s disease. Acad. Radiol. 2009, 16, 597–603.
[CrossRef]
17. Buisson, A.; Joubert, A.; Montoriol, P.F.; Ines, D.D.; Hordonneau, C.; Pereira, B.; Garcier, J.M.; Bommelaer, G.;
Petitcolin, V. Diffusion-weighted magnetic resonance imaging for detecting and assessing ileal inflammation
in Crohn’s disease. Aliment. Pharmacol. Ther. 2013, 37, 537–545. [CrossRef]
18. Kim, K.-J.; Lee, Y.; Park, S.H.; Kang, B.-K.; Seo, N.; Yang, S.-K.; Ye, B.D.; Park, S.H.; Kim, S.Y.; Baek, S.; et al.
Diffusion-weighted MR Enterography for Evaluating Crohn’s Disease: How Does It Add Diagnostically to
Conventional MR Enterography? Inflamm. Bowel Dis. 2015, 21, 101–109. [CrossRef]
19. Kopylov, U.; Klang, E.; Yablecovitch, D.; Lahat, A.; Avidan, B.; Neuman, S.; Levhar, N.; Greener, T.;
Rozendorn, N.; Beytelman, A.; et al. Magnetic resonance enterography versus capsule endoscopy activity
indices for quantification of small bowel inflammation in Crohn’s disease. Therap. Adv. Gastroenterol. 2016, 9,
655–663. [CrossRef]
Diagnostics 2020, 10, 347 19 of 21
20. Hordonneau, C.; Buisson, A.; Scanzi, J.; Goutorbe, F.; Pereira, B.; Borderon, C.; Da Ines, D.; Montoriol, P.F.;
Garcier, J.M.; Boyer, L.; et al. Diffusion-weighted magnetic resonance imaging in ileocolonic Crohn’s disease:
Validation of quantitative index of activity. Am. J. Gastroenterol. 2014, 109, 89–98. [CrossRef]
21. Drake-Pérez, M.; Boto, J.; Fitsiori, A.; Lovblad, K.; Vargas, M.I. Clinical applications of diffusion weighted
imaging in neuroradiology. Insights Imaging 2018, 9, 535–547. [CrossRef] [PubMed]
22. Javier Sánchez-González, J.L.-M. Diffusion-Weighted Imaging: Acquisition and Biophysical Basis. In Diffusion
MRI Outside the Brain: A Case-Based Review and Clinical Applications; Springer: Berlin/Heidelberg, Germany,
2012; pp. 1–15.
23. Kwee, T.C.; Takahara, T.; Ochiai, R.; Katahira, K.; Van Cauteren, M.; Imai, Y.; Nievelstein, R.A.J.; Luijten, P.R.
Whole-body diffusion-weighted magnetic resonance imaging. Eur. J. Radiol. 2009, 70, 409–417. [CrossRef]
[PubMed]
24. Del Grande, F.; Santini, F.; Aro, M.R.; Gold, G.E.; Carrino, J.A. Fat-Suppression Techniques for 3-T MR
Imaging of the Musculosceletal system. Radiographics 2014, 34, 217–233. [CrossRef] [PubMed]
25. Indrati, R. Comparing SPIR and SPAIR Fat Suppression Techniques in Magnetic Resonance Imaging (MRI)
of Wrist Joint. J. Med. Sci. Clin. Res. 2017, 05, 23180–23185. [CrossRef]
26. Horger, W. Fat Suppression in the Abdomen (Siemens). MAGNETOM Flash 2007, 3, 114–119.
27. Takahara, T.; Imai, Y.; Yamashita, T.; Yasuda, S.; Nasu, S.; Van Cauteren, M. Diffusion weighted whole body
imaging with background body signal suppression (DWIBS): Technical improvement using free breathing,
STIR and high resolution 3D display. Radiat. Med. 2004, 22, 275–282. [PubMed]
28. Moore, W.A.; Khatri, G.; Madhuranthakam, A.J.; Sims, R.D.; Pedrosa, I. Added value of diffusion-weighted
acquisitions in MRI of the abdomen and pelvis. Am. J. Roentgenol. 2014, 202, 995–1006. [CrossRef]
29. Ouyang, Z.; Ouyang, Y.; Zhu, M.; Lu, Y.; Zhang, Z.; Shi, J.; Li, X.; Ren, G. Diffusion-weighted imaging with fat
suppression using short-tau inversion recovery: Clinical utility for diagnosis of breast lesions. Clin. Radiol.
2014, 69, e337–e344. [CrossRef]
30. Kwee, T.C.; Takahara, T.; Ochiai, R.; Nievelstein, R.A.J.; Luijten, P.R. Diffusion-weighted whole-body imaging
with background body signal suppression (DWIBS): Features and potential applications in oncology. Eur.
Radiol. 2008, 18, 1937–1952. [CrossRef]
31. Stadlbauer, A.; Salomonowitz, E.; Bernt, R.; Haller, J.; Gruber, S.; Bogner, W.; Pinker, K.; van der Riet, W.
Diffusion-weighted MR imaging with background body signal suppression (DWIBS) for the diagnosis of
malignant and benign breast lesions. Eur. Radiol. 2009, 19, 2349–2356. [CrossRef]
32. “American College of Radiology, WWW.ACR.ORG,” ACR–SAR–SPR Practice Parameter for the Performance
of Magnetic Resonance (MR) Enterography. Available online: https://www.acr.org/-/media/ACR/Files/
Practice-Parameters/MR-Enterog.pdf (accessed on 1 March 2020).
33. Sinha, R.; Rajiah, P.; Ramachandran, I.; Sanders, S.; Murphy, P.D. Diffusion-weighted MR imaging of
the gastrointestinal tract: Technique, indications, and imaging findings. Radiographics 2013, 33, 655–676.
[CrossRef] [PubMed]
34. Park, S.H. Bowel Inflammation in Crohn Disease. Am. J. Roentgenol. 2016, 207, 40–48. [CrossRef]
35. Kiryu, S.; Dodanuki, K.; Takao, H.; Watanabe, M.; Inoue, Y.; Takazoe, M.; Sahara, R.; Unuma, K.; Ohtomo, K.
Free-breathing diffusion-weighted imaging for the assessment of inflammatory activity in Crohn’s disease.
J. Magn. Reson. Imaging 2009, 29, 880–886. [CrossRef]
36. Kwee, T.C.; Takahara, T.; Koh, D.M.; Nievelstein, R.A.J.; Luijten, P.R. Comparison and reproducibility of
ADC measurements in breathhold, respiratory triggered, and free-breathing diffusion-weighted MR imaging
of the liver. J. Magn. Reson. Imaging 2008, 28, 1141–1148. [CrossRef]
37. Jeong, K.K.; Kyoung, A.K.; Park, B.W.; Kim, N.; Cho, K.S. Feasibility of diffusion-weighted imaging in the
differentiation of metastatic from nonmetastatic lymph nodes: Early experience. J. Magn. Reson. Imaging
2008, 28, 714–719.
38. Stone, A.J.; Browne, J.E.; Lennon, B.; Meaney, J.F.; Fagan, A.J. Effect of motion on the ADC quantification
accuracy of whole-body DWIBS. Magn. Reson. Mater. Phys. Biol. Med. 2012, 25, 263–266. [CrossRef]
[PubMed]
39. Rimola, J.; Rodriguez, S.; García-Bosch, O.; Ordás, I.; Ayala, E.; Aceituno, M.; Pellisé, M.; Ayuso, C.; Ricart, E.;
Donoso, L.; et al. Magnetic resonance for assessment of disease activity and severity in ileocolonic Crohn’s
disease. Gut 2009, 58, 1113–1120. [CrossRef]
Diagnostics 2020, 10, 347 20 of 21
40. Moy, M.P.; Sauk, J.; Gee, M.S. The role of MR enterography in assessing Crohn’s disease activity and treatment
response. Gastroenterol. Res. Pract. 2016, 2016, 8168695. [CrossRef] [PubMed]
41. Nardone, O.M.; Iacucci, M.; Cannatelli, R.; Zardo, D.; Ghosh, S. Can advanced endoscopic techniques for
assessment of mucosal inflammation and healing approximate histology in inflammatory bowel disease?
Ther. Adv. Gastroenterol. 2019, 12, 1756284819863015. [CrossRef] [PubMed]
42. Zorzi, F.; Stasi, E.; Bevivino, G.; Scarozza, P.; Biancone, L.; Zuzzi, S.; Rossi, C.; Pallone, F.; Calabrese, E. A
Sonographic Lesion Index for Crohn’s Disease Helps Monitor Changes in Transmural Bowel Damage During
Therapy. Clin. Gastroenterol. Hepatol. 2014, 12, 2071–2077. [CrossRef]
43. Civitelli, F.; Nuti, F.; Oliva, S.; Messina, L.; La Torre, G.; Viola, F.; Cucchiara, S.; Aloi, M. Looking beyond
Mucosal Healing: Effect of Biologic Therapy on Transmural Healing in Pediatric Crohn’s Disease. Inflamm.
Bowel Dis. 2016, 22, 2418–2424. [CrossRef] [PubMed]
44. Serban, E.D. Treat-to-target in Crohn’s disease: Will transmural healing become a therapeutic endpoint?
World J. Clin. Cases 2018, 6, 501–513. [CrossRef] [PubMed]
45. Castiglione, F.; Imperatore, N.; Testa, A.; De Palma, G.D.; Nardone, O.M.; Pellegrini, L.; Caporaso, N.;
Rispo, A. One-year clinical outcomes with biologics in Crohn’s disease: Transmural healing compared with
mucosal or no healing. Aliment. Pharmacol. Ther. 2019, 49, 1026–1039. [CrossRef] [PubMed]
46. Ordás, I.; Rimola, J.; Alfaro, I.; Rodríguez, S.; Castro-Poceiro, J.; Ramírez-Morros, A.; Gallego, M.; Giner, À.;
Barastegui, R.; Fernández-Clotet, A.; et al. Development and Validation of a Simplified Magnetic Resonance
Index of Activity for Crohn’s Disease. Gastroenterology 2019, 157, 432–439. [CrossRef] [PubMed]
47. Steward, M.J.; Punwani, S.; Proctor, I.; Adjei-Gyamfi, Y.; Chatterjee, F.; Bloom, S.; Novelli, M.; Halligan, S.;
Rodriguez-Justo, M.; Taylor, S.A. Non-perforating small bowel Crohn’s disease assessed by MRI enterography:
Derivation and histopathological validation of an MR-based activity index. Eur. J. Radiol. 2012, 81, 2080–2088.
[CrossRef]
48. Buisson, A.; Hordonneau, C.; Goutte, M.; Boyer, L.; Pereira, B.; Bommelaer, G. Diffusion-weighted magnetic
resonance imaging is effective to detect ileocolonic ulcerations in Crohn’s disease. Aliment. Pharmacol. Ther.
2015, 42, 452–460. [CrossRef]
49. Buisson, A.; Hordonneau, C.; Goutorbe, F.; Allimant, C.; Goutte, M.; Reymond, M.; Pereira, B.; Bommelaer, G.
Bowel wall healing assessed using magnetic resonance imaging predicts sustained clinical remission and
decreased risk of surgery in Crohn’s disease. J. Gastroenterol. 2018, 54, 312–320. [CrossRef]
50. Chilla, G.S.; Tan, C.H.; Xu, C.; Poh, C.L. Diffusion weighted magnetic resonance imaging and its recent
trend-a survey. Quant. Imaging Med. Surg. 2015, 5, 407–422. [PubMed]
51. Novacek, G.; Gröchenig, H.P.; Haas, T.; Wenzl, H.; Steiner, P.; Koch, R.; Feichtenschlager, T.; Eckhardt, G.;
Mayer, A.; Kirchgatterer, A.; et al. Diagnostic delay in patients with inflammatory bowel disease in Austria.
Wien. Klin. Wochenschr. 2019, 131, 104–112. [CrossRef]
52. Caruso, A.; D’Incà, R.; Scarpa, M.; Manfrin, P.; Rudatis, M.; Pozza, A.; Angriman, I.; Buda, A.; Sturniolo, G.C.;
Lacognata, C. Diffusion-weighted magnetic resonance for assessing ileal Crohn’s disease activity. Inflamm.
Bowel Dis. 2014, 20, 1575–1583. [CrossRef]
53. Kinner, S.; Blex, S.; Maderwald, S.; Forsting, M.; Gerken, G.; Lauenstein, T.C. Addition of diffusion-weighted
imaging can improve diagnostic confidence in bowel MRI. Clin. Radiol. 2014, 69, 372–377. [CrossRef]
[PubMed]
54. Ninivaggi, V.; Missere, M.; Restaino, G.; Gangemi, E.; Di Matteo, M.; Pierro, A.; Sallustio, G.; Bonomo, L.
MR-enterography with diffusion weighted imaging: ADC values in normal and pathological bowel loops, a
possible threshold ADC value to differentiate active from inactive Crohn’s disease. Eur. Rev. Med. Pharmacol.
Sci. 2016, 20, 4540–4546. [PubMed]
55. Tielbeek, J.A.W.; Ziech, M.L.W.; Li, Z.; Lavini, C.; Bipat, S.; Bemelman, W.A.; Roelofs, J.J.T.H.; Ponsioen, C.Y.;
Vos, F.M.; Stoker, J. Evaluation of conventional, dynamic contrast enhanced and diffusion weighted MRI for
quantitative Crohn’s disease assessment with histopathology of surgical specimens. Eur. Radiol. 2014, 24,
619–629. [CrossRef] [PubMed]
56. Zhu, J.; Zhang, F.; Liu, F.; He, W.; Tian, J.; Han, H.; Cao, P. Identifying the inflammatory and fibrotic bowel
stricture: MRI diffusion-weighted imaging in Crohn’s disease. Radiol. Infect. Dis. 2015, 2, 128–133. [CrossRef]
57. Morani, A.C.; Smith, E.A.; Ganeshan, D.; Dillman, J.R. Diffusion-Weighted MRI in Pediatric Inflammatory
Bowel Disease. Am. J. Roentgenol. 2015, 204, 1269–1277. [CrossRef]
Diagnostics 2020, 10, 347 21 of 21
58. Geboes, K. Histopathology of Crohn’s Disease and Ulcerative Colitis. In Inflammatory Bowel Diseases;
Satsangi, J.S.L., Ed.; Churchill-Livingstone Elsevier: Edinburgh, Scotland; London, UK; Melbourne, Australia,
2003; Volume 18, pp. 255–276.
59. Feakins, R.M. Inflammatory bowel disease biopsies: Updated British Society of Gastroenterology reporting
guidelines. J. Clin. Pathol. 2013, 66, 1005–1026. [CrossRef]
60. Magro, F.; Langner, C.; Driessen, A.; Ensari, A.; Geboes, K.; Mantzaris, G.J.; Villanacci, V.; Becheanu, G.;
Nunes, P.B.; Cathomas, G.; et al. European consensus on the histopathology of inflammatory bowel disease.
J. Crohn’s Colitis 2013, 7, 827–851. [CrossRef]
61. Roger, M.; Feakins, N.A.S. An update on the pathology of chronic inflammatory bowel disease. In Recent
Advances in Histopathology 23; Massimo Pignatelli, P.G., Ed.; JP Medical Ltd.: London, UK, 2014; pp. 117–134.
ISBN 9781907816857.
62. Robert Riddell, D.J. Gastrointestinal Pathology and its Clinical Implications, 2nd ed.; Lippincott Williams &
Wilkins, Ed.; Wolters Kluwer: Philadelphia, PA, USA, 2014; Volume II, ISBN 9780781722162.
63. Li, X.A.; Zhou, Y.; Zhou, S.X.; Liu, H.R.; Xu, J.M.; Gao, L.; Yu, X.J.; Li, X.H. Histopathology of melanosis coli
and determination of its associated genes by comparative analysis of expression microarrays. Mol. Med. Rep.
2015, 12, 5807–5815. [CrossRef]
64. Lambert, J.R.; Luk, S.C.; Pritzker, K.P. Brown bowel syndrome in Crohn’ disease. Arch. Pathol. Lab. Med.
1980, 104, 201–205.
65. Liu, Z.H.; Fooo, D.C.C.; Law, W.L.; Chan, F.S.Y.; Fan, J.K.M.; Peng, J.S. Melanosis coli: Harmless pigmentation?
A case-control retrospective study of 657 cases. PLoS ONE 2017, 12, e0186668. [CrossRef]
66. González Ballester, M.Á.; Zisserman, A.P.; Brady, M. Estimation of the partial volume effect in MRI. Med.
Image Anal. 2002, 6, 389–405. [CrossRef]
67. Scherrer, B.; Gholipour, A.; Warfield, S.K. Super-Resolution in Diffusion-Weighted Imaging Benoit. Med.
Image Comput. Comput. Assist. Interv. 2011, 14, 124–132. [PubMed]
68. Choi, S.H.; Kim, K.W.; Lee, J.Y.; Kim, K.J.; Park, S.H. Diffusion-weighted Magnetic Resonance Enterography
for Evaluating Bowel Inflammation in Crohn’s Disease: A Systematic Review and Meta-analysis. Inflamm.
Bowel Dis. 2016, 22, 669–679. [CrossRef]
69. Aggarwal, R.; Ranganathan, P. Common pitfalls in statistical analysis: The use of correlation techniques.
Perspect. Clin. Res. 2016, 7, 187–190.
70. Apine, I.; Pirksta, I.; Pitura, R.; Pokrotnieks, J.; Puíîte, I.; Krûmiòa, G. Repeatability of Magnetic Resonance
Measurements Used for Estimating Crohn’s Disease Activity. Proc. Latv. Acad. Sci. Sect. B Nat. Exact Appl.
Sci. 2020, 74, 75–82. [CrossRef]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
